New combo therapy aims to improve sarcoma surgery outcomes

NCT ID NCT07396116

Not yet recruiting Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial is testing whether giving a special type of radiation (ultra-hypofractionated) along with immunotherapy before surgery is safe and feasible for people with retroperitoneal sarcoma. The study will enroll 28 participants. The main goal is to see how many patients have complications around the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ultra-hypofractionated radiotherapy combined with immunotherapy
What this could lead to: If successful, this could point toward a new treatment approach that improves surgical outcomes for retroperitoneal sarcoma.
What could go wrong: This is a very early, small trial (28 people) focused on safety, not effectiveness. The combination may increase side effects or not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

radiation injury retroperitoneal sarcoma sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNOTHERAPY RADIOTHERAPY SIDE EFFECT RETROPERITONEAL SARCOMA SOFT TISSUE SARCOMA (STS) ULTRA-HYPOFRACTIONATED RADIOTHERAPY

Contacts and locations

Locations

Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.